Reata Pharmaceuticals closes CATALYST study of bardoxolone methyl for connective tissue disease-associated pulmonary arterial hypertension .
Related news and insights
United Therapeutics Corporation announced the submission of a new drug application (NDA) to the FDA for Tyvaso DPI, a novel dry powder inhalation formulation of treprostinil, for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1 pulmonary hypertension) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3 pulmonary hypertension).
Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with Uptravi (selexipag) from Johnson & Johnson, either maintained (56%) or reduced (20%) their one-year mortality risk score.
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation announced that the FDA has issued a complete response letter (CRL) for the company’s New Drug Application (NDA) for LIQ 861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).